Overview of Familial Mediterranean Fever (FMF)
Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder and is recognized as the most prevalent monogenic autoinflammatory condition globally. Characterized by recurrent bouts of inflammation and serositis that resolve on their own, FMF is inherited through an autosomal recessive pattern due to mutations in the MEFV gene located on chromosome 16p13.3. This gene encodes for pyrin, a crucial regulatory protein in the innate immune response. These genetic mutations ultimately lead to excessive secretion of interleukin-1 beta (IL-1β), resulting in systemic inflammatory episodes. The disease predominantly affects individuals from Mediterranean populations, including Arabs, Armenians, Turks, Sephardic Jews, and North Africans, with prevalence rates estimated between 1 in 1,000 and 1 in 3,000 in high-risk groups.
Research Findings from Oujda, Morocco
This study aimed to elucidate the clinical, epidemiological, biological, and genetic characteristics of pediatric FMF cases in the Oriental region of Morocco. Conducted as a retrospective descriptive study over an 11.5-year period from January 2015 to June 2026 at the Mohammed VI University Hospital in Oujda, the research included 14 children diagnosed with FMF based on established pediatric criteria and confirmed through genetic analysis. The findings revealed a mean diagnosis age of 6.5 years, with a notable male predominance (85.7%). Parental consanguinity was present in 35.7% of cases, underlining the genetic aspects of this condition.
Clinical manifestations were consistent across the cohort, with 100% experiencing recurrent fever, 85.7% reporting abdominal pain, and 78.6% suffering from arthralgia or arthritis. Genetic testing showcased that 64.3% of patients had identifiable MEFV mutations, with the M694V variant being the most prevalent. The study highlighted several diagnostic challenges through four illustrative case reports, where atypical presentations led to significant delays in diagnosis, emphasizing the necessity for heightened clinical awareness and prompt genetic testing. Notably, colchicine therapy was effective in all cases, with no instances of amyloid amyloidosis observed during the follow-up period, suggesting a successful management approach. This research underscores the importance of rigorous clinical evaluation and genetic confirmation in facilitating early diagnosis and treatment initiation for pediatric FMF patients in regions with limited resources.
As reported by cureus.com.
